Iovance Biotherapeutics Financials - Benzinga

Iovance Biotherapeutics Inc

IOVANASDAQ

Trade with Public

Trade with Public

$6.57

0.233.63%

Last update: Aug 10, 12:17 PM

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 4 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Iovance Biotherapeutics Financials

Iovance Biotherapeutics (IOVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.

Evette Mitkov

PRO
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.

Benzinga Newsdesk

PRO
Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate

Benzinga Newsdesk

PRO
Iovance Biotherapeutics Sees FY2026 Sales $350.000M-$370.000M vs $370.477M Est

Iovance Biotherapeutics (NASDAQ:IOVA) sees FY2026 sales of $350.000 million-$370.000 million vs $370.477 million analyst estimate.

Benzinga Newsdesk

PRO
Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 47.22 percent increase over losses of $(0.36) per

Benzinga Newsdesk

PRO
Iovance Biotherapeutics Q4 EPS $(0.18) Misses $(0.17) Estimate, Sales $86.771M Beat $80.361M Estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 6.51 percent. This is a 30.77 percent increase over losses of $(0.26) per

Benzinga Newsdesk